Home > Boards > US Listed > Biotechs > Ariad Pharmaceuticals, Inc. (ARIA)

A relevant excerpt from the patent application:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
iandy Member Profile
 
Followed By 9
Posts 2,610
Boards Moderated 1
Alias Born 06/09/10
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/17/2014 5:04:08 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/17/2014 5:03:50 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/17/2014 5:03:01 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/17/2014 5:02:36 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/17/2014 5:01:27 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/17/2014 5:00:31 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/17/2014 4:59:24 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/17/2014 4:58:30 PM
ARIAD to Webcast Conference Call on Second Quarter 2014 Financial Results "Business Wire" - 7/16/2014 7:35:00 AM
ARIAD Announces Continuation of Iclusig Review under the Article 20 Procedure in Europe "Business Wire" - 7/14/2014 7:35:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/27/2014 4:29:03 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/26/2014 6:02:16 AM
Amended Securities Registration (section 12(b)) (8-a12b/a) "Edgar (US Regulatory)" - 6/24/2014 4:55:54 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/24/2014 4:51:59 PM
ARIAD Announces Three Key Appointments to Its Global Management Team "Business Wire" - 6/23/2014 7:35:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 6/19/2014 4:43:54 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/19/2014 7:58:38 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 6/19/2014 7:54:47 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/17/2014 4:54:48 PM
ARIAD Announces Pricing of $200 Million Offering of 3.625% Convertible Senior Notes Due 2019 "Business Wire" - 6/12/2014 9:15:00 AM
ARIAD Announces Proposed $175 Million Offering of Convertible Senior Notes Due 2019 "Business Wire" - 6/11/2014 4:01:00 PM
ARIAD Announces Webcast of Its Annual Shareholders Meeting "Business Wire" - 6/11/2014 7:35:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/5/2014 4:06:47 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/4/2014 4:30:03 PM
ARIAD Announces Longer-Term Safety and Efficacy Data of Ponatinib from PACE and Phase 1 Clinical Trials "Business Wire" - 6/2/2014 7:30:00 AM
iandy   Friday, 07/12/13 07:16:59 AM
Re: jaybe post# 32123
Post # of 51614 
A relevant excerpt from the patent application:

>There is no cure for PD. Current therapy relies heavily on replenishing dopamine by giving patients oral doses of a dopaminergic agent like the dopamine precursor levodopa (alone or in the combination carbidopa levodopa) or a dopamine agonist. Such therapy can provide relief, although with the increasing risk of serious side effects and often with diminishing therapeutic results, requiring increasing doses as treatment continues, and more serious side effects. There is a profound need for additional therapeutics for PD.

c-Abl is a major regulator of parkin function and phosphorylates parkin on tyrosine 143. This phosphorylation inhibits parkin's E3 ubiquitin ligase activity leading to

accumulation of AIMP2 and FBP1 and loss of parkin's cytoprotective function and cell death. One Abl inhibitor, STI-571 , has been found to maintain parkin in a catalytically active and neuroprotective state by preventing phosphorylation of parkin. As such, it is believed that inhibition of c-Abl presents a viable approach for the treatment of PD. o, et al., PNAS, 107(38), 16691 -16696 (2010). One challenge of using STI-571 to treat PD is that it has poor penetration of the blood-brain barrier as demonstrated in mice and humans. Thus, there is a need for Abl inhibitors that cross the blood-brain barrier for the treatment of PD.

Applicant's own WO 2007/075869, which is hereby incorporated herein by reference for all purposes, discloses certain compounds that inhibit inter alia Abl. One notable Abl inhibitor is ponatinib, which is currently the subject of a clinical trial to determine the efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with Ph positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the T315I mutation of Bcr-Abl (clinical trials.gov identifier NCT01207440). WO 2007/075869 does not explicitly mention using such Abl inhibitors for the treatment of PD.

SUMMARY

It has been unexpectedly discovered that certain Abl inhibitors cross the blood brain barrier and are useful in the regulation of parkin and accordingly for the treatment of PD.<



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist